Stock Track | Ardelyx Plunges 9.50% in Pre-Market on Q4 Earnings Miss and Widening Annual Losses

Stock Track

Feb 20

Ardelyx Inc. (NASDAQ: ARDX) experienced a significant pre-market plunge of 9.50% on Friday. This movement follows a sharp decline in post-market and after-hours trading the previous day.

The sell-off was triggered by the release of the company's fourth-quarter and full-year 2025 financial results. Ardelyx reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01. This result represents a 95% decrease compared to earnings of $0.02 per share from the same period last year.

Although quarterly revenue of $125.2 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning annual trend. The biopharmaceutical company's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024, indicating ongoing challenges in achieving profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137136425"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137136425\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137136425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137136425","market":"us","top_or_hot":-1,"title":"Stock Track | Ardelyx Plunges 9.50% in Pre-Market on Q4 Earnings Miss and Widening Annual Losses","media":"Stock Track","content":"<p>Ardelyx Inc. (NASDAQ: ARDX) experienced a significant pre-market plunge of 9.50% on Friday. This movement follows a sharp decline in post-market and after-hours trading the previous day.</p><p>The sell-off was triggered by the release of the company's fourth-quarter and full-year 2025 financial results. Ardelyx reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01. This result represents a 95% decrease compared to earnings of $0.02 per share from the same period last year.</p><p>Although quarterly revenue of $125.2 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning annual trend. The biopharmaceutical company's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024, indicating ongoing challenges in achieving profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Plunges 9.50% in Pre-Market on Q4 Earnings Miss and Widening Annual Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Plunges 9.50% in Pre-Market on Q4 Earnings Miss and Widening Annual Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ardelyx Inc. (NASDAQ: ARDX) experienced a significant pre-market plunge of 9.50% on Friday. This movement follows a sharp decline in post-market and after-hours trading the previous day.</p><p>The sell-off was triggered by the release of the company's fourth-quarter and full-year 2025 financial results. Ardelyx reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01. This result represents a 95% decrease compared to earnings of $0.02 per share from the same period last year.</p><p>Although quarterly revenue of $125.2 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning annual trend. The biopharmaceutical company's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024, indicating ongoing challenges in achieving profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1137136425","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137136425","pubTimestamp":1771581053,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ardelyx Inc. (NASDAQ: ARDX) experienced a significant pre-market plunge of 9.50% on Friday. This movement follows a sharp decline in post-market and after-hours trading the previous day.The sell-off...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"个股追踪|Ardelyx盘前暴跌9.50%因Q4盈利未达预期且年度亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Ardelyx Inc. (NASDAQ: ARDX) experienced a significant pre-market plunge of 9.50% on Friday. This movement follows a sharp decline in post-market and after-hours trading the previous day.The sell-off was triggered by the release of the company's fourth-quarter and full-year 2025 financial results. Ardelyx reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01. This result represents a 95% decrease compared to earnings of $0.02 per share from the same period last year.Although quarterly revenue of $125.2 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning annual trend. The biopharmaceutical company's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024, indicating ongoing challenges in achieving profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}